This review systematically summarizes the core pathophysiological mechanisms by which inflammatory and immune dysfunctions contribute to AD pathogenesis and explores potential therapeutic interventions targeting these mechanisms, thereby providing theoretical insights for clinical translational research on AD treatment.
Abstract
Alzheimer's Disease (AD) is an age-related neurodegenerative disorder of the Central Nervous System (CNS), characterized by amyloid-β (Aβ) deposition and Neurofibrillary Tangles (NFTs) caused by the hyperphosphorylation of tau protein. Neuroinflammation is an increasingly recognized feature of AD, playing a critical role in disrupting the immune microenvironment within the brain parenchyma. High levels of various inflammatory mediators have been documented in both AD patients and experimental AD models. Similarly, multiple immune cells have been found to accumulate in the brain parenchyma, the meninges, and the choroid plexus. Therefore, antiinflammatory therapies, including Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), and immune regulatory strategies hold promise as potential novel approaches for the prevention and treatment of AD. Currently, a variety of anti-inflammatory agents and immunotherapies have demonstrated efficacy in AD animal models, and several clinical trials of immunotherapeutic interventions have been completed or are underway. This review systematically summarizes the core pathophysiological mechanisms by which inflammatory and immune dysfunctions contribute to AD pathogenesis and explores potential therapeutic interventions targeting these mechanisms, thereby providing theoretical insights for clinical translational research on AD treatment.
The phenotypic and functional alterations of B cells in AD are reviewed, integrating evidence from experimental models and human studies to evaluate whether B cells constitute an underappreciated component of the adaptive immune response in AD and whether they represent a compelling immunotherapeutic target.
Eva-Loren Charavner, S. Fillatreau, M. El Behi· Cellular Immunology· 0 citations
This review examines the molecular and cellular mechanisms through which neuroinflammation contributes to the progression of AD, with particular emphasis on microglial activation, TREM2 and soluble TREM2 (sTREM2) signaling, NLRP3 inflammasome activation, astrocyte–microglia interactions, and blood–brain barrier dysfunc...
Shreyansh Goswami· International Journal For Mu...· 0 citations
Current preclinical and emerging evidence indicate that the modulation of interconnected pathological pathways, including mitochondrial dysfunction, insulin resistance, and neuroinflammation, may lead to improved therapeutic outcomes, and the incorporation of early diagnostic biomarkers in conjunction with the use of m...
Lalit Parihar, A. Singh, Sanjar Alam· Current Pharmacogenomics and...· 0 citations
Findings support a move from general anti-inflammatory treatment toward stage-based, biomarker-guided immune regulation, which may reduce cytokine damage while maintaining microglial clearance and repair, and support developing immune-regulating treatments for AD.
Ya-Wen Deng· Theoretical and Natural Scie...· 0 citations
Alzheimer’s disease (AD) is the most common neurodegenerative disorder in older adults, characterized by progressive cognitive decline that ultimately leads to severe dementia. The primary pathophysiological hallmarks of AD include the accumulation of amyloid-β plaques, neurofibrillary tangles composed of hyperphosphor...
Salvatore Vaiasicca, G. Mangiaterra, Barbara Citterio et al.· Frontiers in Cellular and In...· 0 citations
This review provides a comprehensive overview of cytokine-mediated neuroinflammation in Alzheimer's disease, focusing on the cellular sources of cytokine production within the brain, including microglia, astrocytes, neurons, and endothelial cells.
R. Wasim· InflammoPharmacology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.